16842380

Source:http://linkedlifedata.com/resource/pubmed/id/16842380

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0025677, umls-concept:C0087111, umls-concept:C0221102, umls-concept:C1516213, umls-concept:C1521761
pubmed:issue	1
pubmed:dateCreated	2006-7-17
pubmed:abstractText	To characterize determinants of the elimination of methotrexate (MTX) and 7-hydroxy-methotrexate (7-OH-MTX) in patients receiving high-dose MTX therapy (HDMTX).
pubmed:commentsCorrections	http://linkedlifedata.com/resource/pubmed/commentcorrection/16842380-10912581, http://linkedlifedata.com/resource/pubmed/commentcorrection/16842380-10981249, http://linkedlifedata.com/resource/pubmed/commentcorrection/16842380-11108434, http://linkedlifedata.com/resource/pubmed/commentcorrection/16842380-1116135, http://linkedlifedata.com/resource/pubmed/commentcorrection/16842380-11459208, http://linkedlifedata.com/resource/pubmed/commentcorrection/16842380-12008196, http://linkedlifedata.com/resource/pubmed/commentcorrection/16842380-12077038, http://linkedlifedata.com/resource/pubmed/commentcorrection/16842380-12130730, http://linkedlifedata.com/resource/pubmed/commentcorrection/16842380-14500392, http://linkedlifedata.com/resource/pubmed/commentcorrection/16842380-15139068, http://linkedlifedata.com/resource/pubmed/commentcorrection/16842380-15248210, http://linkedlifedata.com/resource/pubmed/commentcorrection/16842380-15313923, http://linkedlifedata.com/resource/pubmed/commentcorrection/16842380-15864128, http://linkedlifedata.com/resource/pubmed/commentcorrection/16842380-2231218, http://linkedlifedata.com/resource/pubmed/commentcorrection/16842380-2787331, http://linkedlifedata.com/resource/pubmed/commentcorrection/16842380-2868265, http://linkedlifedata.com/resource/pubmed/commentcorrection/16842380-2872506, http://linkedlifedata.com/resource/pubmed/commentcorrection/16842380-2894526, http://linkedlifedata.com/resource/pubmed/commentcorrection/16842380-302412, http://linkedlifedata.com/resource/pubmed/commentcorrection/16842380-3153222, http://linkedlifedata.com/resource/pubmed/commentcorrection/16842380-3500051, http://linkedlifedata.com/resource/pubmed/commentcorrection/16842380-3814725, http://linkedlifedata.com/resource/pubmed/commentcorrection/16842380-3874719, http://linkedlifedata.com/resource/pubmed/commentcorrection/16842380-3971482, http://linkedlifedata.com/resource/pubmed/commentcorrection/16842380-6342775, http://linkedlifedata.com/resource/pubmed/commentcorrection/16842380-6353235, http://linkedlifedata.com/resource/pubmed/commentcorrection/16842380-6956440, http://linkedlifedata.com/resource/pubmed/commentcorrection/16842380-7049375, http://linkedlifedata.com/resource/pubmed/commentcorrection/16842380-7160050, http://linkedlifedata.com/resource/pubmed/commentcorrection/16842380-7189691, http://linkedlifedata.com/resource/pubmed/commentcorrection/16842380-7546826, http://linkedlifedata.com/resource/pubmed/commentcorrection/16842380-8040679, http://linkedlifedata.com/resource/pubmed/commentcorrection/16842380-8054251, http://linkedlifedata.com/resource/pubmed/commentcorrection/16842380-8249043, http://linkedlifedata.com/resource/pubmed/commentcorrection/16842380-8269594, http://linkedlifedata.com/resource/pubmed/commentcorrection/16842380-8500226, http://linkedlifedata.com/resource/pubmed/commentcorrection/16842380-8697606
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/7503323
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antimetabolites, Antineoplastic, http://linkedlifedata.com/resource/pubmed/chemical/Methotrexate
pubmed:status	MEDLINE
pubmed:month	Jul
pubmed:issn	0306-5251
pubmed:author	pubmed-author:BaasPP, pubmed-author:BeijnenJ HJH, pubmed-author:HuitemaA D RAD, pubmed-author:JoergerMM, pubmed-author:SchellensJ H MJH, pubmed-author:SchornagelJ HJH, pubmed-author:van den BongardH J G DHJ
pubmed:issnType	Print
pubmed:volume	62
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	71-80
pubmed:dateRevised	2009-11-18
pubmed:meshHeading	pubmed-meshheading:16842380-Antimetabolites, Antineoplastic, pubmed-meshheading:16842380-Dose-Response Relationship, Drug, pubmed-meshheading:16842380-Female, pubmed-meshheading:16842380-Humans, pubmed-meshheading:16842380-Infusions, Intravenous, pubmed-meshheading:16842380-Male, pubmed-meshheading:16842380-Metabolic Clearance Rate, pubmed-meshheading:16842380-Methotrexate, pubmed-meshheading:16842380-Middle Aged, pubmed-meshheading:16842380-Neoplasms
pubmed:year	2006
pubmed:articleTitle	Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients.
pubmed:affiliation	Department of Pharmacy & Pharmacology, Slotervaart Hospital/The Netherlands Cancer Institute, Amsterdam, and Department of Biomedical Analysis, Faculty of Pharmaceutical Sciences, Utrecht University, The Netherlands. apmsj@slz.nl
pubmed:publicationType	Journal Article, Research Support, Non-U.S. Gov't